On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...